Early Extracorporeal Shockwave Therapy for Erectile Dysfunction in Radically Prostatectomised Men.
Erectile Dysfunction, Extracorporeal Shockwave Therapy, Radical Prostatectomy
About this trial
This is an interventional prevention trial for Erectile Dysfunction focused on measuring Radical Prostatectomy, Prostatectomy, Nerve-sparing, Non nerve-sparing, Erectile dysfunction, Erectile function, Shockwave, LI-ESWT, ESWT, Low intensity extracorporeal shockwave therapy, extracorporeal shockwave therapy
Eligibility Criteria
Inclusion Criteria:
- Radically prostatectomised men
- Non nerve-sparing or nerve-sparing RP.
- Age 20-80 years
- Have been in a relationship for more than 3 months.
- Sexually active
- Patient can give informed consent.
Exclusion Criteria:
- Men with ED of neuropathological or psychogenic origin
- Rectal extirpation, radiation therapy to the pelvic area and recovery from any other cancer within the past 5 years are excluded.
- Patients with heart disease prohibiting sexual activity or taking medication with antiandrogens, anticoagulant (apart from aspirin) or systemic use of glucocorticoids within 5 weeks.
Sites / Locations
- Odense University Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Sham Comparator
Active LI-ESWT
Sham
Active group receives five sessions of low intensity extracorporeal shockwave treatment, once per week for five consecutive weeks. Treatment is initiated three weeks after radical prostatectomy and is given using DUOLITH® SD1 manufactured by STORZ MEDICAL AG.
Sham group receives five sessions of sham low intensity extracorporeal shockwave treatment, once per week for five consecutive weeks. Treatment is initiated three weeks after radical prostatectomy and is given using DUOLITH® SD1 manufactured by STORZ MEDICAL AG with a shockwave absorbing adapter.